Recursion to Acquire Exscientia for $688M in AI-Powered Deal
Recursion Pharmaceuticals acquires Exscientia to enhance AI drug discovery, potentially saving millions in drug development costs.
- Latest
- Trending
Recursion Pharmaceuticals acquires Exscientia to enhance AI drug discovery, potentially saving millions in drug development costs.
Exscientia merges into Recursion to form a $850 million AI drug discovery powerhouse, focusing on oncology and rare diseases.
Ethereum whales invest heavily in Mpeppe, a new DeFi token combining meme culture with ETH technology.
National Vision reports Q2 revenue rise; focuses on tech and strategic shifts for future growth amid economic challenges.
Discover how NFT games are revolutionizing the gaming industry, allowing players to earn unique digital assets while they play.
Comscore's Q2 2024 earnings show a decline in revenue but highlight a strategic shift towards growth by Q4 2024.
Inspire Medical Systems reports a 30% revenue increase in Q2 2024, with net income of $9.8 million, and raises full-year ...
Rivian posts a Q2 loss of $1.46 per share, missing estimates as production declines; teams up with Volkswagen in a ...
Volkswagen will invest up to $5B in Rivian to develop advanced EV technology, aiming to launch new vehicles by the ...
Goldman Sachs rates Disney's robust content and parks, and Fox's news and sports strengths as **Buy**; Paramount's hurdles earn a ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.